Logo

MDS Reports 5-Percent Organic Growth in Analytics Revenue

Jun 07, 2007
NEW YORK (GenomeWeb News) — MDS today reported that second-quarter revenue for its MDS Analytical Technologies segment, which now includes MDS Sciex and Molecular Devices, increased 54 percent, although organic growth was 5 percent.
 
Total revenue for the three months ended March 31 increased to $88 million from $57 million. The majority of the increase came from recently acquired Molecular Devices, which MDS bought in March for $615 million. The company also recorded $3 million in expenses from the acquisition.  
 
R&D spending increased to $7 million from $1 million year over year.  
 
MDS said its services revenue drove growth and profitability.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.